Lonafarnib in Metastatic Breast Cancer

Summary

A published phase 2 study reported that lonafarnib was administered as a single agent via continuous or intermittent oral dosing to 76 women with advanced breast cancer who were previously treated with chemotherapy and/or with endocrine therapy. Objective response rates of approximately 10% were observed. This study will determine the rate of progression-free survival of patients with metastatic breast cancer who receive lonafarnib.

Timeline

Start

2008-10

Primary completion

2010-11

Completion

2010-11

Drugs

Indications